Biotech
Aug. 28, 2014
Lawyers brace for biosimilar patent litigation
The highly contentious Affordable Care Act was signed into law by President Barack Obama four years ago. Lost in the debate over healthcare was a part of the statute that could spur a new wave of patent litigation filings in the biotechnolo
Four years after the Affordable Care Act became law, biotechnology companies are preparing for an influx of high-stakes, big-money lawsuits that could represent a major boon to patent litigation specialists.
These incoming lawsuits ask federal judges to determine which companies will be allowed to offer generic pharmaceutical products known as biosimilars to customers, and which companies will be excluded from the lucr...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In